Premium
Association between serial dynamic contrast‐enhanced MRI and dynamic 18 F‐FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer
Author(s) -
Partridge Savannah C.,
Vanantwerp Risa K.,
Doot Robert K.,
Chai Xiaoyu,
Kurland Brenda F.,
Eby Peter R.,
Specht Jennifer M.,
Dunnwald Lisa K.,
Schubert Erin K.,
Lehman Constance D.,
Mankoff David A.
Publication year - 2010
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.22362
Subject(s) - medicine , breast cancer , dynamic contrast enhanced mri , dynamic contrast , chemotherapy , positron emission tomography , neoadjuvant therapy , nuclear medicine , radiology , breast mri , oncology , magnetic resonance imaging , cancer , mammography
Purpose To investigate the relationship between changes in vascularity and metabolic activity measured by dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI) and dynamic 18 F‐FDG‐positron emission tomography (PET) in breast tumors undergoing neoadjuvant chemotherapy. Materials and Methods PET and MRI examinations were performed in 14 patients with locally advanced breast cancer (LABC) before and after chemotherapy. Dynamic 18 F‐FDG PET measures included 18 F‐FDG transport rate constant from blood to tissue (K 1 ) and metabolism flux constant (Ki). DCE‐MRI measures included initial peak enhancement (PE), signal enhancement ratio (SER), and tumor volume. Spearman rank‐order correlations were assessed between changes in PET and MRI parameters, and measures were compared between patients with and without pathologic complete response (pCR) by Mann–Whitney U ‐test. Results Changes in glucose delivery (PET K 1 ) were closely correlated with changes in tumor vascularity as reflected by DCE‐MRI SER ( r = 0.83, P < 0.001). Metabolic changes in PET Ki showed moderate correlations with vascularity changes as reflected by SER ( r = 0.71) and PE ( r = 0.76), and correlated closely with MRI tumor volume ( r = 0.79, P < 0.001). Decreases in K 1 , Ki, SER, and PE were greater for patients with pCR compared to those with residual disease ( P < 0.05). Conclusion Dynamic 18 F‐FDG PET and DCE‐MRI tumor measures of tumor metabolism, vascularity, and volume were well correlated for assessing LABC response to neoadjuvant chemotherapy and significantly discriminated pathologic complete responders. Further work is necessary to assess the value of combined PET and MRI for evaluating tumor pharmacodynamics in response to novel therapy. J. Magn. Reson. Imaging 2010;32:1124–1131. © 2010 Wiley‐Liss, Inc.